The graphs BGJ398 molecular weight of Kaplan-Meier estimates were plotted using Stata statistical software v. 8.2 (College Station, TX). All personal identifiers were removed before the linked data were transferred for data analysis. Because there were no identifiers or links to identifiers in this

dataset, the study was exempt from human subjects review by the Committee on Human Research at the Johns Hopkins Bloomberg School of Public Health, including a waiver of the requirement for informed consent of participating women. Among 1,782,401 women tested, the mean age (standard deviation) at their last HBV seromarker test was 28.29 (4.57) years, as reported.16 In brief, the prevalence of HBsAg seropositivity among the total population and the prevalence of HBeAg seropositivity among HBV-infected carriers with known HBeAg serostatus were 16% (289,992/1,782,401) and 29% (68,390/233,916), respectively. Women in the cohort were followed for a mean of 6.91 years, with a total follow-up

time of 2,105,434 person-years in the HBV-infected subpopulation and 10,206,674 person-years in the HBV-uninfected subpopulation. In total, 18 women had been diagnosed with ICC, whereas 192 women were newly diagnosed NHLs. As for their HBV carrier status at the time of last HBV test: nine were HBsAg-seronegative and nine were HBsAg-seropositive in ICCs, and 125 and 67 in NHLs, respectively. Of the 18 women with newly diagnosed ICC, 15 had histology information; 14 were “Bile Duct Adenocarcinoma” (histology code, 8160), and one was “Adenocarcinoma, NOS” Z-VAD-FMK purchase (histology code, 8140). The most common NHL subtype was diffuse large B-cell lymphoma (51.6%), followed by follicular lymphoma (9.4%), peripheral T-cell lymphoma (7.3%), small lymphocytic lymphoma and mantle cell lymphoma (5.2%), mycosis fungoides and Sezary’s disease (5.2%), and Burkitt lymphoma (4.2%). Only one case of lymphoplasmacytic lymphoma and one case of NK/T-cell lymphoma occurred during the study period. There were selleck products 31 cases in the category of other NHL, including 28 cases of “NHL, NOS” and three

cases of “malignant lymphoma, lymphoblastic” (Table 1). Table 2 shows incidence rates of developing ICC, NHL overall, and NHL subtypes by HBsAg serostatus. The overall incidence rate (95% CI) per 100,000 person-years was 0.15 (0.09-0.23) for ICC and 1.56 (1.35-1.80) for NHL. Women seropositive for HBsAg had significantly increased incidence rates of ICC and NHL than HBsAg-seronegative women. The incidence rates (95% CI) per 100,000 person-years of ICC were 0.09 (0.05-0.17) and 0.43 (0.22-0.82), respectively, for HBsAg-seronegative and HBsAg-seropositive women; and 1.23 (1.03-1.46) and 3.18 (2.50-4.04), respectively, of NHL. The significantly increased risk also was observed for two NHL subtypes, diffuse large B-cell lymphoma and other NHL. The incidence rates per 100,000 person-years of diffuse large B-cell lymphoma increased from HBsAg-seronegative (0.60; 95% CI, 0.47-0.77) to HBsAg-seropositive (1.81; 1.31-2.48) women.